Quick Takeaways
- Clearline Capital LP filed SCHEDULE 13G/A for HERON THERAPEUTICS, INC. /DE/ Common Stock, par value $0.01 per share (HRTX).
- Disclosed ownership: 6.7%.
- Date of event: 31 Dec 2025.
Clearline Capital LP - 31 Dec 2025 SCHEDULE 13G/A Report for HERON THERAPEUTICS, INC. /DE/ Common Stock, par value $0.01 per share (HRTX)
- Filing Manager
- Clearline Capital LP
- Reporting Manager
- Clearline Capital LP
- Symbol
- HRTX
- Shares outstanding
- 182,615,507 shares
- Disclosed Ownership
- 12,235,239 shares
- Ownership
- 6.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 14:40:59 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 26 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Clearline Capital LP disclosed 6.7% ownership in HERON THERAPEUTICS, INC. /DE/ Common Stock, par value $0.01 per share (HRTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 26 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 14:40.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Clearline Capital LP | 6.7% | 12,235,239 | 0 | 12,235,239 | Marc Majzner | Limited Partner | |
| Clearline Capital LLC | 6.7% | 12,235,239 | 0 | 12,235,239 | Marc Majzner | Managing Member | |
| Marc Majzner | 6.7% | 12,235,239 | 0 | 12,235,239 | Marc Majzner | Authorized Signatory |